open access

Ahead of Print
Research paper
Published online: 2021-11-18
Get Citation

Overall survival (OS) in patients after chemotherapy for cervical cancer in Poland in years 2008–2015

Waldemar Wierzba12, Mateusz Jankowski3, Krzysztof Placiszewski2, Piotr Ciompa1, Artur J. Jakimiuk45, Anna Danska-Bidzinska6
DOI: 10.5603/GP.a2021.0155
Affiliations
  1. University of Humanities and Economics in Łódź, Łódź, Poland
  2. Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland
  3. School of Public Health, Centre of Postgraduate Medical Education, Warsaw, Poland
  4. Department of Obstetrics and Gynecology, Central Clinical Hospital of Interior Affairs and Administration, Warsaw, Poland
  5. Center of Reproductive Health, Institute of Mother and Child, Warsaw, Poland
  6. Chair and Department of Obstetrics, Gynaecology and Oncology, 2nd Faculty of Medicine, Medical University of Warsaw, Warsaw, Poland

open access

Ahead of Print
ORIGINAL PAPERS Gynecology
Published online: 2021-11-18

Abstract

Objectives: To analyze cervical cancer prevalence as well as treatment methods, and its effects and assessment of overall survival of patients after chemotherapy for cervical cancer in Poland. Material and methods: Data were collected from the registry of the National Health Fund (the only public payer in Poland). The data of patients treated in 2008–2015, who were shown to the payer with the diagnosis of malignant neoplasm of cervix (C53 according to the ICD-10 classification), were included in the analysis. The annual and eight-year prevalence rates were calculated. The overall survival was calculated for patients treated with chemotherapy. Results: In the analyzed period (2008–2015), 83,100 women were diagnosed with C53, of which 33,300 (40%) were reported in the group of hospital treatment. The median age of patients was 59 years (58.8 ± 12.87). The highest prevalence rate was observed in 2008 (16.94 patients/100,000 inhabitants). The highest annual and period (2008–2015) prevalence rates patients per 100,000 inhabitants were observed in the Podlaskie (17.03 and 115.53 respectively) and Pomorskie (14.19 and 101.43 respectively) voivodeships and the lowest in Dolnośląskie voivodeship (10.47 and 78.87 respectively) and Podkarpackie voivodeship (10.79 and 71.29 respectively). Mean survival time was 55.12 months and its median 45.46 months. Annual survival time was observed in 76.79% of patients, 2-year in 60.61%; 3-year in 53.08% and 5-year in 46.65%. Conclusions: In the years 2008–2015 in Poland, the incidence of cervical cancer was even 4 times higher than the EU average, and the mortality was as much as 70% higher than the average for EU countries.

Abstract

Objectives: To analyze cervical cancer prevalence as well as treatment methods, and its effects and assessment of overall survival of patients after chemotherapy for cervical cancer in Poland. Material and methods: Data were collected from the registry of the National Health Fund (the only public payer in Poland). The data of patients treated in 2008–2015, who were shown to the payer with the diagnosis of malignant neoplasm of cervix (C53 according to the ICD-10 classification), were included in the analysis. The annual and eight-year prevalence rates were calculated. The overall survival was calculated for patients treated with chemotherapy. Results: In the analyzed period (2008–2015), 83,100 women were diagnosed with C53, of which 33,300 (40%) were reported in the group of hospital treatment. The median age of patients was 59 years (58.8 ± 12.87). The highest prevalence rate was observed in 2008 (16.94 patients/100,000 inhabitants). The highest annual and period (2008–2015) prevalence rates patients per 100,000 inhabitants were observed in the Podlaskie (17.03 and 115.53 respectively) and Pomorskie (14.19 and 101.43 respectively) voivodeships and the lowest in Dolnośląskie voivodeship (10.47 and 78.87 respectively) and Podkarpackie voivodeship (10.79 and 71.29 respectively). Mean survival time was 55.12 months and its median 45.46 months. Annual survival time was observed in 76.79% of patients, 2-year in 60.61%; 3-year in 53.08% and 5-year in 46.65%. Conclusions: In the years 2008–2015 in Poland, the incidence of cervical cancer was even 4 times higher than the EU average, and the mortality was as much as 70% higher than the average for EU countries.

Get Citation

Keywords

cervical cancer; epidemiology; survival rate; Poland

About this article
Title

Overall survival (OS) in patients after chemotherapy for cervical cancer in Poland in years 2008–2015

Journal

Ginekologia Polska

Issue

Ahead of Print

Article type

Research paper

Published online

2021-11-18

DOI

10.5603/GP.a2021.0155

Keywords

cervical cancer
epidemiology
survival rate
Poland

Authors

Waldemar Wierzba
Mateusz Jankowski
Krzysztof Placiszewski
Piotr Ciompa
Artur J. Jakimiuk
Anna Danska-Bidzinska

References (12)
  1. International Agency for Research on Cancer. Global Cancer Observatory. https://gco.iarc.fr/databases.php (2021.05.01).
  2. World Health Organization. Health topics: Cancer. https://www.who.int/health-topics/cancer#tab=tab_1 (2021.05.01).
  3. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3): 209–249.
  4. Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. The Lancet Global Health. 2020; 8(2): e191–e203.
  5. European Commission. ECIS - European Cancer Information System. https://ecis.jrc.ec.europa.eu/ (2021.05.01).
  6. Michalska M. Epidemiologia raka szyjki macicy. . In: Spaczyńsk M, Kędzia W, Nowak-Markwitz E. ed. Rak szyjki macicy. Profilaktyka, diagnostyka i leczenie. Wyd Lek PZWL, Warszawa 2009.
  7. Wojciechowska U, Didkowska J. Zachorowania i zgony na nowotwory złośliwe w Polsce. Krajowy Rejestr Nowotworów, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy. http://onkologia.org.pl/raporty/ (2021.05.01).
  8. Brisson M, Kim J, Canfell K, et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. The Lancet. 2020; 395(10224): 575–590.
  9. Saville AM. Cervical cancer prevention in Australia: Planning for the future. Cancer Cytopathol. 2016; 124(4): 235–240.
  10. Kuczborska K, Kacperczyk-Bartnik J, Wolska M, et al. Secondary cervical cancer prevention in routine prenatal care - coverage, results and lessons for the future. Ginekol Pol. 2019; 90(7): 396–402.
  11. Spaczyński M, Karowicz-Bilinska A, Kedzia W, et al. Costs of population cervical cancer screening program in Poland between 2007-2009. Ginekol Pol. 2010; 81(10): 750–756.
  12. Januszek-Michalecka L, Nowak-Markwitz E, Banach P, et al. Effectiveness of the National Population-Based Cervical Cancer Screening Programme in Poland--outcomes, problems and possible solutions 7 years after implementation. Ann Agric Environ Med. 2013; 20(4): 859–864.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl